FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nancy Martin

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Intestinal Absorption

Devices

Phenomena

Permeability

Co-author Network

Publications

TOP 3
Iolanda Cirillo; Nancy E Martin; Barbara Brennan; Jeffrey S Barrett
The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Gary T Emmons; Rick Argenti; Louis L Martin; Nancy E Martin; Bradford K Jensen
Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Marc Pfister; Nancy E Martin; Lloyd P Haskell; Jeffrey S Barrett
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nancy Martin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2004: Iolanda Cirillo; Nancy E Martin; Barbara Brennan; Jeffrey S Barrett
The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Journal of clinical pharmacology 2004;44(12):1379-84.
2004: Gary T Emmons; Rick Argenti; Louis L Martin; Nancy E Martin; Bradford K Jensen
Pharmacokinetics of M100240 and MDL 100,173, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy young and elderly volunteers.
Journal of clinical pharmacology 2004;44(8):901-5.
2004: Marc Pfister; Nancy E Martin; Lloyd P Haskell; Jeffrey S Barrett
Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240.
Journal of clinical pharmacology 2004;44(6):621-31.
2004: Nancy E Martin; Stanley R Howell; Louis L Martin; Iolanda Cirillo; Jeffrey S Barrett
No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
Journal of clinical pharmacology 2004;44(4):379-87.
2003: Kin-Kai Hwang; Nancy E Martin; Lan Jiang; Chengyue Zhu
Permeation prediction of M100240 using the parallel artificial membrane permeability assay.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Société canadienne des sciences pharmaceutiques 2003;6(3):315-20.
2003: Bharti Shah; Gary Emmons; Shashank Rohatagi; Nancy E Martin; Bradford K Jensen
Mass balance study of [14C]M100240, a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, in healthy male subjects.
American journal of therapeutics 2003;10(5):356-62.
2003: Nancy E Martin; Kathryn R Collison; Louis L Martin; Sarah Tardif; Ian R Wilding; Heather Wray; Jeffrey S Barrett
Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.
Journal of clinical pharmacology 2003;43(5):529-38.
2002: Kin-Kai Hwang; Lan Jiang; Ying Ren; Louis L Martin; Nancy E Martin
Site-specific absorption of M100240 and MDL 100,173 in rats evaluated using Sweetana-Grass diffusion chamber technology.
Journal of pharmacological and toxicological methods 2002;48(2):97-101.